This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams GK et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 8: 2951–2959.
Flotho C, Coustan-Smith E, Pei D, Cheng C, Song G, Pui CH et al. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukaemia. Blood 2007; 4: 1271–1277.
Staal FJT, van der Burg M, Wessels LFA, Barendrecht BH, Baert MR, van den Burg CM et al. DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor B-acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia 2003; 17: 1324–1332.
Beesley AH, Cummings AJ, Freitas JR, Hoffmann K, Firth MJ, Ford J et al. The gene expression signature of relapse in pediatric ALL: implications for mechanisms of therapy failure. Br J Hematol 2005; 131: 447–456.
Bhojwani D, Kang H, Moskowitz NP, Min DJ, Lee H, Potter JW et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a children's Oncology Group Study. Blood 2006; 108: 711–717.
Schmidt S, Rainer J, Riml S, Plomer C, Jesacher S, Achmüller C et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukaemia. Blood 2006; 5: 2061–2069.
Tissing WJ, den Boer ML, Meijerink JP, Menezes RX, Swagemakers S, van der Spek PJ et al. Genome-wide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 2007; 9: 3929–3935.
de Haas V, Verhagen OJ, von dem Borne AEGKr, Kroes W, van den Berg H, van der Schoot CE . Quantification of minimal residual disease in children with oligoclonal B-precursor ALL indicates that the clones that grow out during relapse have the slowest rate of reduction already during induction therapy. Leukemia 2001; 15: 134–140.
de Haas V, Breunis WB, Verhagen OJ, van den Berg H, van der Schoot CE . Accurate quantification of MRD at day-15, by real-time quantitative PCR identifies also patients with B-precursor ALL at high risk for relapse. Blood 2000; 96: 1619–1620.
Acknowledgements
This study was funded by a grant from the Dutch Cancer Society (Grant nr UVA2005-3230).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Haas, V., Dee, R., Cheroutre, G. et al. Gene expression profile of slowly responding subclones might represent different profiles already at diagnosis and might be used for prediction of outcome. Leukemia 23, 816–819 (2009). https://doi.org/10.1038/leu.2008.315
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.315